Through this study, we noticed that TMDCD can down-regulate 16 differential expressed proteins such as Fractalkine, Tryptase ε, IL-25, CCL19, MCP-1, OX40L, Axl, CCL22, CD30, G-CSF, E-selectin, OPN, CCL5, P-selectin, Gas6, and TSLP, which may be the key target of TMDCD in the treatment of allergic asthma. The gene discussed is CCL22; the disease is allergic asthma.